Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Subjects With Advanced Adenocarcinoma of the Lung

Next Previous
X
Search
Trial Profile

An Open-Label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Subjects With Advanced Adenocarcinoma of the Lung

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pemlimogene-merolisbac (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Janssen Research & Development

    • Most Recent Events

    • 04 Jun 2019 Results evaluating immunogenicity, safety, and efficacy of JNJ-757 in patients with advanced NSCLC (adenocarcinoma) as monotherapy (phase 1) and in combination with nivolumab (phase 1b/2) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
    • 16 May 2019 According to a Bristol-Myers Squibb Media Release, data from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4, and the 24th Annual Congress of the European Hematology Association (EHA) in Amsterdam, June 13-16.
    • 07 Nov 2018 Status changed from active, no longer recruiting to discontinued as development of JNJ-64041757 in combination with nivolumab discontinued due to lack of clinical benefit observed in the Phase 1b portion of the study

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top